Preparation of specific anti-Helicobacter pylori yolk antibodies and their antibacterial effects.
OBJECTIVE
To study immunization procedures and preparation methods of specific IgY antibodies (IgY-Hp, IgY-IB) produced by hens immunized with Helicobacter pylori (Hp) bacterial antigen and recombinant Hp specific antigen IB, detect the inhibition effects on Hp growth and Hp urease activity, and study the effects of oral administration for treating Hp infection.


METHODS
By using recombinant cholera toxin subunit B (rCTB) as an adjuvant, hens received intramuscular injection immunization for continuous 7 times at an interval of 14 days. Then, the eggs were collected; IgY was purified.


RESULTS
On day 49 after hens were immunized, levels of two antibodies all reached 1:12800; after they were purified by Ammonium sulfate precipitation, their purity was over 80%. IgY-Hp could inhibit Hp growth and inhibit Hp urease activity; although in vitro, IgY-IB could not inhibit Hp growth but could inhibit Hp urease activity. The experiments in vivo found that when IgY-Hp or IgY-IB with sucralfate dual oral therapy was used to treat Hp infected mouse model, the cure rate all could reach 83.3%.


CONCLUSIONS
According to immunization procedure, high titer specific IgY antibody (1:12800) can be obtained in 49 days and its titer remains stable. Oral administration of the specific IgY antibodies in Hp infected mice can reach a cure rate of 83.3%, and the antibodies are expected to become new drugs and therapeutic methods of targeted therapy against Hp infection.
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China.
Baoning
B
Wang
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China ; Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China ; Department of Medical Microbiology, School of Preclinical Medicine, Hubei University of Medicine Shiyan 442000, China.
Jing
J
Yang
College of Veterinary Medicine, Sichuan Agricultural University Ya'an 625014, Sichuan, China.
Suizhong
S
Cao
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China.
Hongren
H
Wang
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China ; Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China.
Xing
X
Pan
Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China.
Jie
J
Zhu
Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China.
Yongjun
Y
Zhou
Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China.
Lizhen
L
Gao
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China.
Wanyi
W
Li
Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China.
Mingyuan
M
Li
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000276:immunology; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000276:immunology; D002645:Chickens; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology; D004195:Disease Models, Animal; D004530:Egg Yolk / Q000276:immunology / Q000378:metabolism*; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D005260:Female; D005756:Gastritis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development / Q000276:immunology*; D007114:Immunization; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000276:immunology; D008297:Male; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013392:Sucralfate / Q000008:administration & dosage / Q000276:immunology; D014510:Urease / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; C016512:IgY; D007136:Immunoglobulins; D013392:Sucralfate; D002772:Cholera Toxin; D014510:Urease
Helicobacter pylori; antibacterial effect; specific IgY